Lupin bags tentative USFDA nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets to control HIV infections

Mumbai: Global pharma major Lupin Limited today announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets.

This product would be manufactured at Lupin’s Nagpur facility in India.

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries, the company stated.

The human immunodeficiency virus (HIV) targets the immune system and weakens people's defense against many infections and some types of cancer that people with healthy immune systems can more easily fight off.

Commenting on the same, Naresh Gupta, President - API and Global Institution Business, Lupin said, “We are committed to providing affordable and quality treatment options to patients in low- and middle income countries. We are pleased that U.S. FDA has tentatively approved DETAF, which will significantly enhance our HIV portfolio."

Read also: Lupin bags USFDA nod for Dolutegravir, Rilpivirine tablets to treat HIV infection